Yoshida, Tsukasa
Hijioka, Susumu
Hosoda, Waki
Ueno, Makoto
Furukawa, Masayuki
Kobayashi, Noritoshi
Ikeda, Masafumi
Ito, Tetsuhide
Kodama, Yuzo
Morizane, Chigusa
Notohara, Kenji
Taguchi, Hiroki
Kitano, Masayuki
Yane, Kei
Tsuchiya, Yoshiaki
Komoto, Izumi
Tanaka, Hiroki
Tsuji, Akihito
Hashigo, Syunpei
Mine, Tetsuya
Kanno, Atsushi
Murohisa, Go
Miyabe, Katsuyuki
Takagi, Tadayuki
Matayoshi, Nobutaka
Sakaguchi, Masafumi
Ishii, Hiroshi
Kojima, Yasushi
Matsuo, Keitaro
Yoshitomi, Hideyuki
Nakamori, Shoji
Yanagimoto, Hiroaki
Yatabe, Yasushi
Furuse, Junji
Mizuno, Nobumasa
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP15ck0106138h0002)
Japan Society for the Promotion of Science (JP26461041)
Article History
Received: 27 August 2018
First Online: 12 March 2019
Disclosures
: Junji Furuse fully declares any financial or other potential conflicts of interest as follows: honoraria from Taiho, Chugai, Yakult, Sumitomo Dainippon, Eli Lilly Japan, Astellas, Ono, Pfizer, Bayer, Novartis, Merck Serono, Takeda, Eisai, MSD, Shionogi, J-Pharma, Daiichi Sankyo, Mochida, Nippon Kayaku, EA Pharma, Sawai, Teijin Pharma; consulting or advisory role with Taiho, Chugai, Yakult, Sumitomo Dainippon, Eli Lilly Japan, Astellas, Ono, Pfizer, Bayer, Novartis, Merck Serono, Takeda, Eisai, MSD, Shionogi, J-Pharma, Daiichi Sankyo, Kyowa Hakko Kirin, Sanofi, Sandoz, Otsuka, Zeria, Fujifilm, Astra Zeneca, Asahi Kasei, Shire; and research funding from J-Pharma, Taiho, Sumitomo Dainippon, Janssen, Daiichi Sankyo, MSD, Yakult, Takeda, Chugai, Ono, Astellas, Zeria, Novartis, Nanocarrier, Shionogi, Onco Therapy Science, Eli Lilly Japan, Bayer, Bristol-Myers Squibb, Merck Serono, Kyowa Hakko Kirin, Eisai, NanoCarrier, Mochida, Baxalta, and Sanofi. Nobumasa Mizuno fully declares any financial or other potential conflicts of interest as follows: honoraria from Taiho, Novartis, Ono Pharmaceutical, Yakult, and Teijin Pharma; advisory role with Teijin Pharma; and research funding from Taiho, Merck Serono, AstraZeneca, Zeria Pharmaceutical, NanoCarrier, Eisai, MSD, Novartis, Dainippon Sumitomo Pharma, ASLAN Pharmaceuticals, Pharma Valley Center, Incyte Inc., and Yakult. Tsukasa Yoshida, Susumu Hijioka, Waki Hosoda, Makoto Ueno, Masayuki Furukawa, Noritoshi Kobayashi, Masafumi Ikeda, Tetsuhide Ito, Yuzo Kodama, Chigusa Morizane, Kenji Notohara, Hiroki Taguchi, Masayuki Kitano, Kei Yane, Yoshiaki Tsuchiya, Izumi Komoto, Hiroki Tanaka, Akihito Tsuji, Syunpei Hashigo, Tetsuya Mine, Atsushi Kanno, Go Murohisa, Katsuyuki Miyabe, Tadayuki Takagi, Nobutaka Matayoshi, Masafumi Sakaguchi, Hiroshi Ishii, Yasushi Kojima, Keitaro Matsuo, Hideyuki Yoshitomi, Shoji Nakamori, Hiroaki Yanagimoto and Yasushi Yatabe declare they have no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.